Effectiveness of Kabasura Kudineer tablets in the management of asymptomatic and mild cases of COVID-19: A pilot double-blinded, randomized controlled trial

• DOI: 10.1016/j.jaim.2023.100777
• Publication Date: 2023-08-01T15:56:55Z
• Authors: Minakshi Khapre; Monika Pathania; Vartika Saxena; Balram JI. Omar; Bela Goyal; Smita Sinha; Yogesh Bahurupi; Puneet Dhamija
• Keywords: Double blinded; Pandemic

COVID-19 was declared a pandemic in 2020. It has had devastating effect on human life and the global economy. To date, there is no proven therapy for COVID-19, even though rigorous research ongoing to test multiple compounds across all systems of medicine. A need felt systematically explore Indian system medicine assess its efficacy against COVID-19. The objective present study examine Kabasura Kudineer as standalone following: time required achieve symptom relief & resolution, virological clearance, levels IL6, CRP IgG, compare it standard available treatment double-blinded randomized controlled trial conducted 110 participants. 55 participants were enrolled arm control (standard + placebo) arm. Study randomly allocated into two arms. They assessed symptoms at baseline, Day 5 10. RT PCR, CRP, IL6 IgG measured On day 28, interviewed telephonically assessment alone. per-protocol approach used. Significant difference between groups 10 using Chi-square Mann Whitney test. total patients participated study. Four 9 Standard lost follow-up. Baseline characteristics both matched baseline. 83.9% 93.9% relieved by 10th respectively. Decrease level more pronounced group compared viz. 3 mg/l 1.26 mg/l. No significant found groups. However, noticed that among unvaccinated group, surge much higher than group. effective safe with asymptomatic mild